Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma - Wikidata - awgldk - TriplyDB

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

http://www.wikidata.org/entity/Q28378420

about

TCR-Engineered T Cells Meet New Challenges to Treat Solid Tumors: Choice of Antigen, T Cell Fitness, and Sensitization of Tumor Milieu Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy Improved survival with vemurafenib in melanoma with BRAF V600E mutation Phase II clinical trial evaluating docetaxel, vinorelbine and GM-CSF in stage IV melanoma Treatment of metastatic melanoma: an overview Progress and controversies in developing cancer vaccines.Melanoma immunotherapy dominates the field Advances in immunotherapy for melanoma Chinese Guidelines on the Diagnosis and Treatment of Melanoma (2015 Edition)Updates in Therapy for Advanced Melanoma Pembrolizumab: First in Class for Treatment of Metastatic Melanoma Epigenetic mechanisms involved in melanoma pathogenesis and chemoresistance The clinical features and optimal treatment of anorectal malignant melanoma Optimal management of metastatic melanoma: current strategies and future directions Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study Inhibition of Mutated, Activated BRAF in Metastatic Melanoma Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility Nivolumab in melanoma: latest evidence and clinical potential Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)Pharmacologic modulation of serine/threonine phosphorylation highly sensitizes PHEO in a MPC cell and mouse model to conventional chemotherapy Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells Surgical management of the patient with metastatic melanoma to the heart.Clinical and histological features of idiosyncratic acute liver injury caused by temozolomide.[Melanoma brain metastases : Treatment options].Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFN alpha in patients with metastatic melanoma.A phase I (tumour site-specific) study of carboplatin and temozolomide in patients with advanced melanoma.Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG).A phase I/II study of lomustine and temozolomide in patients with cerebral metastases from malignant melanoma Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma.A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study.A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1)Multicenter phase II trial of temozolomide in mycosis fungoides/sezary syndrome: correlation with O⁶-methylguanine-DNA methyltransferase and mismatch repair proteins.

P2860

Q21131200-87C48A55-00A5-4109-BF90-124D3153F5CC Q24246409-A0222C2F-3D29-4EF6-B75C-EB3035D3F8FA Q24594790-276EC176-1D76-4F53-80AC-8DF804A376C4 Q24596055-1E8E6F95-A979-4DFF-9599-C192830D2CB1 Q24598856-122ADB4F-1280-4525-BEC6-50F6B0E05FEB Q24631953-057106F1-6EDA-4203-A15F-31490CB84991 Q24635643-85144A60-70C3-4065-AD4D-04D60CFC000E Q24642384-D985DDEA-F013-44FF-9110-1D6CAD1604A0 Q24810256-4EA620CA-9103-4924-B7D0-A4C029D01C91 Q26738671-2A29FE0A-A307-48ED-937F-0CA3F32C047C Q26768558-AB5B6487-9D6B-4C8E-B842-26811674034D Q26770492-29C88407-BA66-4325-9E70-5624140D09F9 Q26771119-09441793-D082-4EAC-A7A7-42CEE0BB5799 Q26777886-D3CB9DC9-EDF9-4A66-B1F9-5676A3C943C9 Q26778761-DF77029A-2803-4154-A54B-B80D5AB2FDF4 Q26828599-8C464039-85D4-4531-8391-6195912ED3C9 Q26997338-0B47FA90-C60B-4EBF-9AC5-34C598075CA3 Q27276774-CB25B6E3-A3F2-4795-B8DD-5559D419C645 Q27860458-1A617BD6-2CFD-4DA7-A396-A5CA04184BD9 Q28078465-FACF78E6-F4CA-4D9D-9317-63A10315E039 Q28258598-4E7A248E-FD38-4BEF-8391-2C89FBC278F1 Q28362951-8D537394-EA21-454E-A906-ECE938E52A43 Q28477147-F2EF342F-F2B8-453D-9A30-D7904221C291 Q28542877-3857ACA8-8AA7-4662-8BB4-AFC05B10A21C Q28728389-C1C14ADA-BABB-47AF-8A23-1D708D47FEE4 Q28730438-3DE081E4-C3A3-48F5-8D0C-FB08BC3B2447 Q29247923-9EC97BE5-7FAC-4487-BEE9-5CC754F6D050 Q30380034-C17F7467-B3C8-4BDD-A05E-0F1E77636EED Q30447260-D5E1E515-C23A-45CE-AE0B-7C64077A75B2 Q31098294-B7146E95-E828-4183-B8B8-1C2407D3A11E Q33346715-E624FB19-A128-4D41-8CDC-08163956E58A Q33357549-19694467-466B-465B-B1D3-C441320DE66B Q33370672-8EEFF149-0F10-4A97-9C19-D3F3C566A5D3 Q33373492-1850D36B-8A2A-4DE5-BC67-AA7FDC310760 Q33382481-C1FF8074-9E6E-41E1-BCCF-AD92ED0EC8A7 Q33384102-A4300432-6DB5-4247-B3E7-2D4E44116A14 Q33390287-292A5C5D-99FC-4DFB-A3EC-0F3FD3B9F83A Q33394173-FD06E3A2-6DFD-4FB0-AF10-90521833D637 Q33394828-154C4AD7-7187-417F-90A9-928AE1724FCD Q33396189-589ACE20-0DF3-42F6-9C8E-BB764BF8DDBD

P2860

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

http://www.wikidata.org/entity/Q28378420

description

2000 nî lūn-bûn

@nan

2000 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Randomized phase III study of ...... metastatic malignant melanoma

@ast

Randomized phase III study of ...... metastatic malignant melanoma

@en

Randomized phase III study of ...... metastatic malignant melanoma

@nl

type

label

Randomized phase III study of ...... metastatic malignant melanoma

@ast

Randomized phase III study of ...... metastatic malignant melanoma

@en

Randomized phase III study of ...... metastatic malignant melanoma

@nl

prefLabel

Randomized phase III study of ...... metastatic malignant melanoma

@ast

Randomized phase III study of ...... metastatic malignant melanoma

@en

Randomized phase III study of ...... metastatic malignant melanoma

@nl

P1433

Q28378420-6F9B099A-26CE-4A8C-90C8-43E50F911181

P1476

Q28378420-EA3BE2DB-86EA-4114-9449-81906FAC24DE

P2093

Q28378420-04831056-6ACD-45CB-A411-E46BBAE92D16

Q28378420-0BC83D4B-5012-44EC-AC25-FC93058BFE3E

Q28378420-1600DC86-D873-4311-9451-515F7D43FBCB

Q28378420-1F529DA7-04D9-4ECE-8565-0F8E93D7F870

Q28378420-1FD14F94-C057-453C-BBF9-1725B61A0166

Q28378420-26FC018A-1D49-4AD0-A27B-65C81F4F1044

Q28378420-46945673-4D5E-4098-97B0-5C52608CD159

Q28378420-4FF64EC1-F590-48E6-98AA-E9A8BFF10885

Q28378420-697DABAA-33E1-4F83-AB24-B911F4F6DB61

Q28378420-74AC9600-1379-4F8B-92CE-9812B551FBAB

P304

Q28378420-4B8E461E-5902-474B-AE49-5218EA548F4A

P31

Q28378420-4C097D2F-7FA2-450F-A0B0-60F6AF13B61D

P3181

Q28378420-D1722BE7-6F5B-4331-8E8D-6EC47C00D821

P356

Q28378420-7317EEEB-70BE-4814-9895-D1380D68E665

P407

Q28378420-22EB7661-7EFC-452C-A87A-476035450703

P433

Q28378420-90097469-2B45-4B0D-8D4F-0E80883041B1

P478

Q28378420-F3262CD0-2C4A-4D46-A62A-646EEB742997

P577

Q28378420-BE92F377-F004-4944-9B07-A23F9FE4B00B

P698

Q28378420-B9A40B9C-48B5-44B3-BC1C-94978F28A5B8

P921

Q28378420-BA1D9E3D-FA8A-4DB1-B1DF-25F3E44CC1C8

P3181

P356

JCO.2000.18.1.158

P1433

Journal of Clinical Oncology

P1476

Randomized phase III study of ...... metastatic malignant melanoma

@en

P2093

A Coates

http://www.w3.org/2001/XMLSchema#string

A Kapp

http://www.w3.org/2001/XMLSchema#string

B Dreno

http://www.w3.org/2001/XMLSchema#string

D Schadendorf

http://www.w3.org/2001/XMLSchema#string

G Fierlbeck

http://www.w3.org/2001/XMLSchema#string

J Cebon

http://www.w3.org/2001/XMLSchema#string

J J Grob

http://www.w3.org/2001/XMLSchema#string

J Weiss

http://www.w3.org/2001/XMLSchema#string

M Gore

http://www.w3.org/2001/XMLSchema#string

M Henz

http://www.w3.org/2001/XMLSchema#string

P304

158-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2714107

http://www.w3.org/2001/XMLSchema#string

P356

10.1200/JCO.2000.18.1.158

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2000-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

10623706

http://www.w3.org/2001/XMLSchema#string

P921